FindTrial
Sign In

MK-2206

DRUG14 trials

Sponsors

Merck Sharp & Dohme LLC, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, Vanderbilt-Ingram Cancer Center, M.D. Anderson Cancer Center

Conditions

Advanced CancerAdvanced Solid TumorsBreast CancerCancerCarcinoma, Non-Small-Cell LungCarcinoma, Small Cell LungCarcinoma, ThymicColon Cancer

Phase 1

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
CompletedNCT00670488
Merck Sharp & Dohme LLCCancer, Locally Advanced Tumors, Metastatic Solid Tumors +1
Start: 2008-04-15End: 2011-07-11Updated: 2019-04-01
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
CompletedNCT00848718
Merck Sharp & Dohme LLCLocally Advanced, Metastatic Solid Tumors
Start: 2009-03-17End: 2012-05-17Updated: 2019-11-12
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
TerminatedNCT00963547
Merck Sharp & Dohme LLCAdvanced Solid Tumors, Breast Cancer
Start: 2009-09-15End: 2011-12-22Updated: 2024-06-04
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
CompletedNCT01021748
Merck Sharp & Dohme LLCLocally Advanced or Metastatic Solid Tumors
Start: 2009-11-23End: 2014-07-16Updated: 2018-08-07
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
CompletedNCT01235897
University of California, San FranciscoAdvanced Solid Tumors, Cancer, Tumors
Start: 2011-03-31End: 2013-11-30Updated: 2014-04-17
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
TerminatedNCT01243762
Merck Sharp & Dohme LLCNeoplasms Malignant
Start: 2010-11-22End: 2013-03-25Updated: 2018-08-16
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
CompletedNCT01295632
Merck Sharp & Dohme LLCAdvanced Cancer
Start: 2011-02-28End: 2015-08-31Updated: 2015-08-27

Phase 2

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
CompletedNCT01169649
Memorial Sloan Kettering Cancer CenterNeuroendocrine, PANCREAS
Start: 2010-07-31End: 2014-02-28Updated: 2016-02-18
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
TerminatedNCT01186705
Memorial Sloan Kettering Cancer CenterColon Cancer, Rectal Cancer
Start: 2010-08-31End: 2011-08-31Updated: 2015-11-18
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
WithdrawnNCT01240941
Vanderbilt-Ingram Cancer CenterMetastatic Breast Cancer
Start: 2011-02-28End: 2012-12-31Updated: 2013-08-20
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
CompletedNCT01248247
M.D. Anderson Cancer CenterLung Cancer
Start: 2011-06-02End: 2020-11-30Updated: 2022-01-12
MK-2206 for Recurrent Malignant Glioma
WithdrawnNCT01249105
Dana-Farber Cancer InstituteMalignant Glioma
Updated: 2016-03-10
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
CompletedNCT01306045
National Cancer Institute (NCI)Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
Start: 2011-02-08End: 2024-07-17Updated: 2024-10-01
MK-2206 in Recurrent Nasopharyngeal Carcinoma
CompletedNCT01370070
Chinese University of Hong KongRecurrent Nasopharyngeal Carcinoma
Start: 2011-07-31End: 2017-01-31Updated: 2017-01-13

Related Papers

Familial lung cancer: A thirteen-year prospective analysis of participants with germline EGFR T790M pathologic variant.
Journal of Clinical Oncology2025-05-28
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
2022-04-0459 citations
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.
2015-07-1860 citations
Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEK
Clinical Cancer Research2014-12-16135 citations
Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Clinical Cancer Research2014-09-1979 citations
BATLLE-2: <i>KRAS</i> mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2014-05-205 citations
Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.
Journal of Clinical Oncology2014-05-202 citations
Results of a phase I trial combining ridaforolimus (mTOR inhibitor) and MK-0752 (Notch inhibitor) in patients with advanced solid tumors.
Journal of Clinical Oncology2014-05-20
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Breast Cancer Research2013-11-19103 citations